Eli Lilly And Company

Omvoh

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Eli Lilly And Company

Omvoh HCPCS:

J2267

HCPCS Code Descriptor:

Inj, mirikizumab-mrkz, 1 mg

Category:

J Code

Omvoh NDCs:

00002-7575-01, 00002-8011-27

Primary Type:

Anti-Fungal

Generic/Specialty Status:

Single-Source

Package Type:

Supplied as Vial, Pen, or Syringe

Route of Administration:

Subcutaneous

Omvoh CPT Codes:

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

We have identified listing errors with the following NDCs:

00002-8870-27, 00002-8011-27

About Omvoh:

Omvoh is a medication manufactured by Eli Lilly And Company and aligned to the J Code: J2267. Omvoh is administered via the Subcutaneous route of administration.

ACCESS PRICING AND MORE BY REGISTERING

J2267 Added Date:

1-Jul-24

J2267 Effective Date:

1-Jul-24

J2267 Termination Date:

HCPCS Active

Our team did not identify patient assistance information for Omvoh
Patient assistance information for Omvoh can be found through Lilly Savings Support at the following URL: https://omvoh.lilly.com/savings-support
Omvoh prescribing information can be found at the link below:
Information regarding Omvoh’s side effect information can be found at Medline Plus.